Abstract
Background and Objectives Parkinson’s disease (PD) progression can be characterized in terms of healthcare utilization by analyzing clinical events across different stages of disease.
Methods PD progression was measured by the Hoehn & Yahr (H&Y) clinical rating scale and clinical events at each stage were evaluated. Natural language processing and a large language model were used to extract H&Y values from real-world data enabling a larger cohort than manually collected studies, and multi-state hidden Markov models were used for H&Y progression likelihood.
Results Within the one year, most patients in H&Y stages 2-5 remained in the same stage. Stage transitions, when they occurred, were most frequently to the next higher stage. Higher H&Y stages were associated with discharges into long term care and higher rates of additional clinical events.
Conclusions Stratifying key clinical events by H&Y score demonstrates the increases of health care utilization and economic burden with PD severity. Modelling the progression likelihood establishes a progression timeline and emphasizes the unmet need to identify treatment options that stop or slow these transitions.
Competing Interest Statement
FF, SB, KJC, are employees of Sanofi and may hold shares and/or stock options in the company. All other authors declare no conflicts of interest.
Funding Statement
This work was funded in part by the Sanofi iDEA Awards Initiative (BKB) as well the National Institute of Neurological Disorders and Stroke grant number (BKB K99NS114850).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Mass General Brigham Institutional Review Board approved this study (protocol #2017P002452).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Authors do not have rights to share data, data from this study were made available from Mass General Brigham and the Harvard Biomarker Study. Authors will share all data upon approval from the data owner.
